Benefyts of lefiunomide in systemic lupus erythematosus: a pilot observational study

Abstract

The objective of this study was to retrospectively explore the safety and efficacy of leflunomide (LEF) in outpatients with systemic lupus erythematosus (SLE).

Eighteen SLE females received LEF, open label, 100 mgday loading dose for 3 days followed by 20 mg per day. Patients were evaluated for safety and efficacy after 2—3 months of therapy.

The mean age was 42.6 y and mean disease duration 7.9 y. ACR criteria were met by 1518. Four patients stopped LEF during the observation period. Ten of 14 LEF-treated patients had subjective improvement with 914 patients achieving lower SLEDAI scores. The mean SLEDAI decreased by 2.1 (P=0.005) and the mean ESR decreased by 9 mm h(P=0.02). Prednisone dosages could be reduced in 25 subjects without a flare. No organ-threatening or life-threatening side effects were seen in our patients. Diarrhea occurred in seven patients (two stopped LEF), rash occurred in one patient (stopped LEF), one patient stopped LEF for reasons not related to therapy. Blood pressure was unchanged.

Leflunomide was efficacious and safe in this cohort of SLE patients after 2—3 months of therapy. Placebo-controlled trials of longer duration are indicated.

Keywords

lefiunomide observational study clinical study DMARD SLE

Get full access to this article

View all access options for this article.

References

Zonana-Nacach A , Barr SG , Magder LS , Petri M . Damage in systemic lupus erythematosus and its association with corticosteroids . Arthrit Rheum 2000; 43: 1801–1808 .

Smolen JS , Kalden JR , Scott DL et al. Effycacy and safety of lefiunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomized, multicentre trial . Lancet 1999; 353: 259–266 .

Bombardier C , Gladman DD , Urowitz MB , Caron D , Chang CH . Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE . Arthrit Rheum 1992; 35: 630–640 .

Fitzgerald JD , Grossman JM . Validity and reliability of retrospective assessment of disease activity and fiare in observational cohorts of lupus patients . Lupus 1999; 8: 638–644 .

Tan EM et al. American College of Rheumatology Criteria for classifycation of SLE . Arthrit Rheum 1992; 25: 1271-1271 .

Arava (lefiunomide) Prescribing information (pamphlet insert). Kansas City, MO: Hoescht Marion Roussel , 1998.

Carneiro JR , Sato EI . Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erthematosus . J Rheumatol 1999; 26: 1275–1279 .

Caccavo D , Lagana B , Mitterhofer AP et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A . Arthrit Rheum 1997; 40: 27–35 .

Ruckemann K , Fairbanks LD , Carrey EA . Lefiunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans . J Biol Chem 1998; 273: 21682–21691 .

10.

Siemasko KF , Chong AS , William JW , Bremer EG , Finnegan A . Regulation of B cell function by the immunosuppressive agent lefiunomide . Transplantation 1996; 61: 635–642 .

11.

Hahn, BH . Pathogenesis of systemic lupus erythematosus. In: Ruddy S , Harris ED , Sledge CB (eds). Kelley's Textbook of Rheumatology. WB Saunders: Philadelphia , 2001, pp 1089–1090.

12.

Weinblatt ME . Methrotrexate. In: Ruddy S , Harris ED , Sledge CB (eds). Kelley's Textbook of Rheumatology. WB Saunders: Philadelphia , 2001, pp 841–852.

13.

Landewe RB , Goei TH , van Rijthoven AW , Rietveld JR , Breedveld FC , Dijkmas BA . Cyclosporine in common clinical practice: an estimation of the benefyt/risk ratio in patients with rheumatoid arthritis . J Rheumatol 1994; 21: 1631–1636 .

14.

Yocum DE , Stein CM , Pincus T . Long-term safety of cyclosporin/Sandimmune alone and in combination with methotrexate in the treatment of active rheumatoid arthritis: analysis of open label extension studies . Arthrit Rheum 1998; 41: S364-S364 .

15.

Petera P , Mander B , Manger K , Rosenburg R , Smolen JS , Kalden JR . A pilot study of lefiunomide in systemic lupus erythematosus . Arthrit Rheum 2000; 43: S241-S241 .